Based on this analysis, alendronate use does not appear to be associated with an
Oral anticoagulation reduces thromboembolic events in patients with
Current alendronate users were associated with a higher risk of atrial
Introduction Bisphosphonates, such as intravenous zoledronic acid (ZA) or oral
Keywords Alendronate
Because the population is aging and age 65 or greater is a strong risk factor for AF, the prevalence of AF Europe PMC is an archive of life sciences journal literature
We conducted a meta-analysis to determine the effects of bisphosphonates on total adverse cardiovascular (CV) events, atrial fibrillation, myocardial infarction (MI), stroke, and CV
sensation of spinning
The oral BSPs alendronate 70 mg once weekly and risedronate 35 mg once weekly (75 mg twice monthly) are the most common used BSPs worldwide
86; 95% confidence interval, 1
infusions of
Bisphosphonate users might differ from nonusers in several ways
A case–controlled study from a healthcare database in the USA found that a greater number of atrial fibrillation case patients than controls had ever used alendronate (6
5% vs 4
Sørensen HT ; Following the publication of 2 clinical trials which found an increased incidence of atrial fibrillation with zoledronic acid, and alendronate, respectively (Black et al, 2007, Cummings et al Bisphosphonates (BPs) are widely prescribed drugs that decrease bone fracture risk in osteoporosis patients
Atrial fibrillation